Canaccord raised the firm’s price target on DexCom (DXCM) to $106 from $103 and keeps a Buy rating on the shares. The firm said they reported a good Q1, beating total and US revenue estimates, while short of OUS estimates but showing strong organic growth OUS.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM: